Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
19
TMCI Quote, Financials, Valuation and Earnings
Last price:
$6.95
Seasonality move
:
13.2%
Day range:
$6.84 - $7.05
52-week range:
$3.92 - $15.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.13x
P/B ratio:
4.13x
Volume:
178.4K
Avg. volume:
396.6K
1-year change:
-42.62%
Market cap:
$433.6M
Revenue:
$187.1M
EPS (TTM):
-$0.99
Analysts' Opinion
-
Consensus RatingTreace Medical Concepts has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.96, Treace Medical Concepts has an estimated upside of 14.37% from its current price of $6.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.50 representing -7.76% downside risk from its current price of $6.96.
Fair Value
-
According to the consensus of 6 analysts, Treace Medical Concepts has 14.37% upside to fair value with a price target of $7.96 per share.
TMCI vs. S&P 500
-
Over the past 5 trading days, Treace Medical Concepts has underperformed the S&P 500 by -9.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Treace Medical Concepts does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Treace Medical Concepts has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Treace Medical Concepts reported revenues of $45.1M.
Earnings Growth
-
Treace Medical Concepts has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Treace Medical Concepts reported earnings per share of -$0.25.
Enterprise value:
404M
EV / Invested capital:
2.55x
Price / LTM sales:
2.13x
EV / EBIT:
--
EV / Revenue:
1.99x
PEG ratio (5yr expected):
-0.27x
EV / Free cash flow:
-9.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$163.5M
Return On Assets:
-26.2%
Net Income Margin (TTM):
-30.33%
Return On Equity:
-49.68%
Return On Invested Capital:
-34.77%
Operating Margin:
-33.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $125.5M | $174.7M | $202.9M | $40.8M | $45.1M | |
| Gross Profit | $103.6M | $141.9M | $163.5M | $32.8M | $36.1M | |
| Operating Income | -$36.9M | -$48.1M | -$62.3M | -$17.8M | -$15.1M | |
| EBITDA | -$39.4M | -$38M | -$48.3M | -$14.7M | -$11.9M | |
| Diluted EPS | -$0.81 | -$0.79 | -$0.99 | -$0.28 | -$0.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $135.4M | $127.9M | $187.1M | $157.6M | |
| Total Assets | -- | $137.6M | $156.4M | $240.4M | $212.9M | |
| Current Liabilities | -- | $10.7M | $22.6M | $33.2M | $38.3M | |
| Total Liabilities | -- | $40.2M | $94.2M | $102.5M | $108M | |
| Total Equity | -- | $97.4M | $62.2M | $137.9M | $104.9M | |
| Total Debt | -- | $29.3M | $52.6M | $52.9M | $53.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$29M | -$40.5M | -$32.4M | -$9.5M | -$11.8M | |
| Cash From Investing | -$13.4M | -$150.3M | $37M | $4.6M | $5.8M | |
| Cash From Financing | $21.5M | $109.5M | $299K | $159K | $8K | |
| Free Cash Flow | -$42.4M | -$52M | -$43.2M | -$13M | -$14.7M | |
TMCI
Sector
Market Cap
$433.6M
$45.6M
Price % of 52-Week High
43.55%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-0.02%
-0.74%
1-Year Price Total Return
-42.62%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.24
200-day SMA
Sell
Level
$7.46
Bollinger Bands (100)
Buy
Level
5.16 - 7.5
Chaikin Money Flow
Sell
Level
-6.1M
20-day SMA
Sell
Level
$7.81
Relative Strength Index (RSI14)
Sell
Level
39.76
ADX Line
Sell
Level
15.31
Williams %R
Buy
Level
-88.9474
50-day SMA
Buy
Level
$6.91
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Sell
Level
-13.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.2908)
Sell
CA Score
(Annual)
Level (-1.159)
Sell
Beneish M-Score
(Annual)
Level (35.5464)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.3041)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
Stock Forecast FAQ
In the current month, TMCI has received 0 Buy ratings 6 Hold ratings, and 0 Sell ratings. The TMCI average analyst price target in the past 3 months is $7.96.
-
Where Will Treace Medical Concepts Stock Be In 1 Year?
According to analysts, the consensus estimate is that Treace Medical Concepts share price will rise to $7.96 per share over the next 12 months.
-
What Do Analysts Say About Treace Medical Concepts?
Analysts are divided on their view about Treace Medical Concepts share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Treace Medical Concepts is a Sell and believe this share price will drop from its current level to $7.50.
-
What Is Treace Medical Concepts's Price Target?
The price target for Treace Medical Concepts over the next 1-year time period is forecast to be $7.96 according to 6 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is TMCI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Treace Medical Concepts is a Hold. 6 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of TMCI?
You can purchase shares of Treace Medical Concepts via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Treace Medical Concepts shares.
-
What Is The Treace Medical Concepts Share Price Today?
Treace Medical Concepts was last trading at $6.95 per share. This represents the most recent stock quote for Treace Medical Concepts. Yesterday, Treace Medical Concepts closed at $6.96 per share.
-
How To Buy Treace Medical Concepts Stock Online?
In order to purchase Treace Medical Concepts stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.05% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.62% over the past day.
